Summary
BeiGene, Ltd. (ONC) filed an 8-K on January 8, 2018, to disclose important updates to investors. The company announced it would be participating in the 36th Annual J.P. Morgan Healthcare Conference, providing a presentation that is attached as an exhibit to this filing. This presentation likely contains key strategic updates and financial outlooks for investors to consider. Furthermore, the filing details a significant licensing agreement entered into with Mirati Therapeutics. This agreement grants BeiGene exclusive rights for the development, manufacturing, and commercialization of Mirati's drug candidate, sitravatinib, across several key Asian territories, Australia, and New Zealand. This strategic move expands BeiGene's pipeline and geographical reach for a promising therapeutic asset.
Key Highlights
- 1BeiGene, Ltd. is attending the 36th Annual J.P. Morgan Healthcare Conference starting January 7, 2018.
- 2A presentation from the J.P. Morgan Conference is included as an exhibit (Exhibit 99.1).
- 3The company has entered into an exclusive license agreement with Mirati Therapeutics.
- 4This agreement covers the development, manufacturing, and commercialization of Mirati's sitravatinib.
- 5The licensed territories for sitravatinib include Asia (excluding Japan), Australia, and New Zealand.
- 6The press release announcing the licensing agreement is attached as Exhibit 99.2.